Garcinia Cambogia

Also sold as: Garcinia gummi-gutta, Hydroxycitric Acid, HCA, Malabar Tamarind

The dried rind of a Southeast Asian fruit, standardized to (-)-hydroxycitric acid — a genuine competitive inhibitor of ATP-citrate lyase, the enzyme that starts fat synthesis. The enzyme block is real. The weight-loss result across twelve randomized trials is under a kilogram.

How Garcinia Cambogia actually works

Hydroxycitric acid is citrate with one extra hydroxyl group, which makes it a structural mimic of citrate and a competitive inhibitor of ATP-citrate lyase — the cytosolic enzyme that cleaves citrate into the acetyl-CoA that de novo lipogenesis is built from. That much is real and is stated in the opening line of the trial that found nothing. What decides the clinical result is the size of the pathway rather than the strength of the inhibition: stable-isotope work that partitioned the sources of liver triglyceride found 59% arriving as fatty acids released from adipose tissue, 26% from de novo lipogenesis and 15% straight from the diet — and that is in people whose lipogenesis is running high. Blocking the small pathway perfectly leaves the large ones untouched. The second mechanism on the label, appetite suppression through serotonin, has no human efficacy data at all; its only appearances in the human record are case reports of serotonin toxicity.

Where to get Garcinia Cambogia

The evidence for Garcinia Cambogia

Graded by what exists behind each claim.

Tested — the evidence is negative

• The 1998 JAMA trial randomized 135 overweight adults to 1500 mg of hydroxycitric acid daily or placebo for 12 weeks on a prescribed high-fiber, low-energy diet. Both groups lost weight; the difference was 3.2 kg on the supplement against 4.1 kg on placebo (P = .14), with no difference in fat mass.
• A meta-analysis of 12 randomized trials found a mean difference of -0.88 kg favoring hydroxycitric acid, with a confidence interval whose upper bound sits on zero, and gastrointestinal side effects roughly twice as frequent as on placebo.
• One randomized trial in women with non-alcoholic fatty liver disease on a calorie-restricted diet did report reduced visceral adipose tissue, with no change in leptin or adiponectin.

📊 Correlative data

• More than 200 reported liver-injury adverse events and 34 published case reports — including one death and nine liver transplants — prompted the US Pharmacopeia to add a cautionary statement to its Garcinia monographs.
• A third of 18 commercial Garcinia products analyzed by chromatography disagreed with their own label on hydroxycitric acid content.

🧪 Theoretical / extrapolated benefits

• The mechanism is sound and the pathway is the wrong size: direct isotope measurement put de novo lipogenesis at 26% of liver triglyceride even in people whose lipogenesis is running high, against 59% arriving from adipose tissue. Blocking the small pathway perfectly leaves the large one untouched.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Garcinia Cambogia actually does

Start with the part that is true, because most of the argument about this plant skips it. The rind of Garcinia gummi-gutta carries (-)-hydroxycitric acid, which is citric acid with one extra hydroxyl group on the carbon backbone. That single substitution makes it a close structural mimic of citrate, and citrate is the substrate of ATP-citrate lyase. The enzyme sits in the cytosol, takes citrate exported from the mitochondrion, and cleaves it into acetyl-CoA and oxaloacetate at the cost of one ATP. Hydroxycitrate occupies the citrate site and does not get cleaved, so it is a COMPETITIVE inhibitor rather than a poison. The 1998 JAMA trial states exactly this in its opening line, which is worth noticing: the trial that found nothing was not written by people who doubted the chemistry Heymsfield 1998.

The inhibition is demonstrable in living cells, not only in a cuvette. Work on tamoxifen-resistant breast cancer cells used hydroxycitric acid specifically as an ATP-citrate lyase inhibitor and reported that the inhibition re-sensitized the resistant line, with matching changes in apoptosis markers Ismail 2022. That is a cell-culture result about cancer biology and it says nothing about waistlines, but it does answer one question cleanly: at concentrations reachable in a dish, this molecule hits this enzyme.

The enzyme is also a serious pharmaceutical target, which rules out the lazy dismissal. The core enzymes of de novo lipogenesis - the citrate/isocitrate carrier, ATP-citrate lyase, acetyl-CoA carboxylase and fatty acid synthase - are being pursued by several classes of synthetic inhibitor now in clinical-stage development, and the reviewers describe the open problems as efficacy, selectivity and safety Batchuluun 2022. Nobody in drug discovery thinks this pathway is imaginary. What they think is that it is hard.

So here is the actual question, and it is arithmetic rather than biochemistry: how much of the fat in a human being came through this enzyme? That has been measured directly. Patients with fatty liver were infused and fed stable isotopes for 4 days so that each source of liver triglyceride could be labeled separately. Of the triglyceride accounted for in liver tissue, 59.0% arrived as non-esterified fatty acids released from adipose tissue, 26.1% came from de novo lipogenesis, and 14.9% came straight from the diet Donnelly 2005. Those are people with the pathway running HIGH. A later study in 123 people with fibrotic steatohepatitis put lipogenesis at a median 40.7% of hepatic palmitate and stated plainly that this is above what has been reported in healthy volunteers Lawitz 2022.

Read that partition against what the supplement claims. A perfect, total, side-effect-free block of ATP-citrate lyase removes the lipogenesis slice and leaves the other two alone. The 59% arriving from adipose lipolysis is set by energy balance and insulin, not by this enzyme. The 15% arriving from the plate is set by what was eaten. And in a person who is not overfed and not carbohydrate-loaded, the lipogenesis slice is smaller still. The lever is real, it is attached to the machine, and it is attached to the part of the machine that is not moving most of the mass. This is the single reason a genuine enzyme inhibitor produces a pooled weight difference of 0.88 kg Onakpoya 2011, and it is a reason nobody selling the capsule has an interest in explaining.

The second mechanism on the label - appetite, through serotonin - has a weaker footing than the first, and its human evidence runs the wrong way. No human study demonstrates a serotonergic effect of hydroxycitric acid at label doses. What the human record contains instead is case reports of serotonin toxicity and mania in people taking these supplements Andueza 2021. A mechanism whose only human appearances are adverse events is not a benefit mechanism; it is an interaction warning, and it is treated as one further down this page.

And the mechanism reappears on the safety side, which is the most interesting thing about this compound. The review that prompted the United States Pharmacopeia to revise its Garcinia monographs lists, among the proposed mechanisms of liver toxicity, hepatocyte apoptosis attributed to hydroxycitric acid's inhibition of ATP-citrate lyase van Breemen 2025. The same enzyme block is offered as the explanation for the harm and as the explanation for the benefit. Take that seriously in both directions: the inhibition is credible enough that toxicologists reach for it, and it is still too small a lever to move a body weight.

Cell, rodent, human — and where it stops

This compound has an unusually clean translation record, and unusually little to show for it.

The cell layer says the enzyme is hit. Hydroxycitric acid used as an ATP-citrate lyase inhibitor changed the behavior of a resistant cancer cell line, with the enzyme block as the stated mechanism Ismail 2022. That is a demonstration in culture at concentrations the experimenter chose, which is exactly what a cell experiment is for and exactly what it cannot be extrapolated from.

The human layer is a proper trial and it is 28 years old. A 12-week randomized, double-blind, placebo-controlled study assigned 135 overweight adults with a mean body mass index near 32 kg/m2 to 1500 mg of hydroxycitric acid per day or placebo, both on a prescribed high-fiber, low-energy diet. Sixty-six went to active and 69 to placebo; 42 in each arm finished. Both groups lost weight, significantly, at p < .001. The between-group difference was 3.2 kg on hydroxycitric acid against 4.1 kg on placebo, p = .14, and there was no difference in fat mass loss Heymsfield 1998. Note the direction: the placebo arm lost more. That is noise, not evidence of harm, but it is not the picture a supplement label paints either.

Pooling the trials moves the number without changing the verdict. A meta-analysis of 12 randomized trials found a mean difference of -0.88 kg favoring hydroxycitric acid, with a 95% confidence interval of -1.75 to -0.00 - an upper bound sitting exactly on zero - and gastrointestinal adverse events occurring twice as often on the supplement as on placebo. The authors called the magnitude modest and its clinical relevance uncertain Onakpoya 2011. An interval that touches zero after 12 trials is not a study-size problem waiting to be solved; it is the answer.

The positive human result, stated in full, because leaving it out would be the same dishonesty in the other direction. A trial in women with non-alcoholic fatty liver disease on a calorie-restricted diet reported that hydroxycitric acid plus the diet significantly reduced visceral adipose tissue, with no significant change in serum leptin or adiponectin Tutunchi 2023. That is one trial, one sex, one disease state, and one background of enforced calorie restriction - and it is the population in which the target pathway is running hardest Donnelly 2005. It is the most encouraging human result this compound has, and it is a reason to run a bigger trial rather than a reason to buy the capsule.

Here is the obstacle that is specific to this literature, and it is not the usual small-sample complaint. Every trial in the pool prescribed a diet as well. An energy deficit suppresses de novo lipogenesis directly and completely, by removing the substrate; a competitive inhibitor suppresses it partially, by competing with a metabolite whose concentration rises when the enzyme backs up. So the contrast being measured is an incomplete block added on top of a complete one. The dietary control of these storage pathways is a live research question with its own methodological problems Roumans 2021, and no garcinia trial has ever measured the pathway it is aimed at.

The second obstacle is the material itself. Eighteen commercial Garcinia weight-loss supplements were analyzed by liquid chromatography; 33% disagreed with their own label on hydroxycitric acid content, and gas chromatography-mass spectrometry found undeclared compounds the authors attributed to heat exposure, excipients or other added extracts Mena-García 2022. Pooling trials by milligrams of extract therefore pools interventions that were not the same intervention, and a reader buying a bottle is not necessarily buying what any of them tested.

Garcinia Cambogia — which form, and does it matter

The form question here is not capsule against powder. It is which salt, how much of it is hydroxycitric acid, and whether a triply charged organic acid can get to a cytosolic enzyme at all.

Start with the label arithmetic, because it changes the whole reading of the evidence. A common panel says something like 1000 mg of Garcinia cambogia extract standardized to 60% hydroxycitric acid. That is 600 mg of the active acid. The JAMA trial that failed used 1500 mg of hydroxycitric acid per day Heymsfield 1998. So a large share of retail products deliver LESS active compound than the dose that produced no effect. The negative trial is not even a fair test of the shelf; it is a test of a bigger dose than most bottles give.

The salt is a real variable and it is under-declared. Hydroxycitric acid is a tricarboxylic acid and is unstable as the free acid, which is why it is sold as a calcium, potassium or mixed calcium-potassium salt. The review of production, extraction and formulation for this plant treats extraction route, salt selection and nanoformulation as the variables that decide the finished product H Baky 2022. A panel that names a percentage but not a salt has declared the number and withheld the thing the number describes.

Now the exposure reasoning, which is where this page has to be honest about what is not known. At intestinal pH hydroxycitrate carries three negative charges. A molecule in that state does not cross a lipid bilayer by diffusion; it needs a carrier, and carriers saturate. Whatever is absorbed then meets first-pass metabolism in the gut wall and liver before it reaches the systemic circulation, and the fraction surviving that - oral bioavailability - has never been reported for a retail garcinia product in a person. That absence is not an inference from silence: the 2022 review presents analytical approaches for detecting Garcinia metabolites in biological fluids, with emphasis on hydroxycitric acid, expressly for the first time and expressly so that pharmacokinetics and proof of efficacy become determinable H Baky 2022. A field publishing its first assay in 2022 has no exposure data behind 25 years of trials.

And absorption is only the first of two membranes. The target is cytosolic. After crossing the gut and surviving the liver, the anion has to cross a second plasma membrane into the hepatocyte or adipocyte and then reach a concentration high enough to compete with citrate, which is present in the cytosol at hundreds of micromolar and which RISES when the enzyme is inhibited. Competitive inhibition is the one kind that the substrate can outrun. Nobody has published the intracellular concentration achieved after an oral dose, and until somebody does, the inhibition constant measured in a tube cannot be turned into a predicted effect in a person.

Practical consequence for a buyer. If the panel does not state a hydroxycitric acid percentage, the dose of the studied molecule is unknown; if it does state one, a third of products tested did not match it Mena-García 2022. Between those two facts, the milligram figure on the front of the bottle is the least informative number on the package.

What would have to be true, and how you would know it was not

1. The weight prediction, at 12 weeks. On a content-verified extract at 1500 mg of hydroxycitric acid per day, predict a difference from placebo of under 1 kg, in the region of the pooled point estimate of -0.88 kg Onakpoya 2011. Weigh at the same time of day across 7 consecutive mornings and compare weekly averages, because the within-person day-to-day standard deviation is wide enough to hide the entire reported effect. If a properly blinded trial on a verified extract produces more than 2 kg beyond placebo, the argument on this page is wrong.

2. The experiment that would actually settle the mechanism, and nobody has run it. Deuterated water labeling, hepatic de novo lipogenesis measured as a fraction of palmitate, before and after 4 weeks on hydroxycitric acid - the same method that quantified lipogenesis at a median 40.7% of palmitate in steatohepatitis Lawitz 2022. Two outcomes, both informative. If lipogenesis does not fall, the compound is not reaching the enzyme in a person and every efficacy argument collapses at the pharmacokinetics. If lipogenesis falls and body weight does not, the enzyme has been hit and the pathway is simply too small to matter, which is what this page predicts.

3. The liver prediction, and it runs in one direction only. A comprehensive metabolic panel and GGT at baseline, 4 weeks and 12 weeks. Predict no change in the overwhelming majority of people, because the documented injury is rare and idiosyncratic rather than dose-dependent van Breemen 2025. Alanine aminotransferase rising above 3 times the upper reference limit, or an alanine aminotransferase to alkaline phosphatase ratio climbing into the hepatocellular range, is a stop signal and a same-week conversation with a clinician - not a detoxification reaction, and not something to wait out.

4. The metabolic prediction, at 12 weeks. HbA1c and fasting insulin. Predict no change on either. Nothing in the pooled randomized evidence claims a glycemic effect, and a compound that shifted insulin sensitivity through lipogenesis inhibition would be a much more interesting product than the one being sold Onakpoya 2011.

5. The prediction that cuts against this page, which is the one that makes it a page rather than a verdict. De novo lipogenesis is the pathway that is elevated in fatty liver - 26.1% of hepatic triglyceride in the isotope study Donnelly 2005, higher again in fibrotic disease Lawitz 2022 - so if hydroxycitrate does anything anywhere, it should do it there, and one randomized trial in women with fatty liver did report a fall in visceral adipose tissue Tutunchi 2023. Predict that a properly powered replication with liver fat by MRI proton density fat fraction as the primary endpoint shows a change too small to be worth the hepatic risk. If it shows a large one, this page has the size of the lever wrong and should be rewritten around fatty liver rather than around weight.

What nobody has tested yet

Nobody has published a plasma concentration-time curve for hydroxycitric acid after a labeled retail dose. Not a Cmax, not a Tmax, not an elimination profile, in any of the 12 pooled trials or since. The analytical methods to do it were being presented as new in 2022 H Baky 2022. Every dose recommendation in this category, including the one on this site's card, is therefore an extrapolation from a trial protocol rather than from an exposure.

Nobody has measured the target pathway under the drug. No garcinia trial has ever quantified de novo lipogenesis in its participants, even though the method has existed for decades and has been run in 123 patients for a different question Lawitz 2022. A supplement sold on an enzyme has never been tested against that enzyme's output in a human being.

Nobody has compared the salts head to head. Calcium, potassium and calcium-potassium hydroxycitrate differ in solubility and therefore plausibly in absorption, and the formulation literature treats the choice as consequential H Baky 2022. Three arms, one dose of hydroxycitric acid, one pharmacokinetic endpoint. It has not been done, and it would cost less than most of the trials that have.

Nobody knows the rate of liver injury, only the numerator. Thirty-four published case reports, one death and nine transplants sit on one side van Breemen 2025; an estimated 15.6 million US adults consuming a liver-liability botanical within a 30-day window sit on the other Likhitsup 2024. Those two numbers are not divisible - the exposure figure covers six botanicals, not garcinia alone - so the honest statement is that the absolute risk is unmeasured and appears low, and that no prospective cohort has ever been assembled to say so properly.

And nobody has tested the genetic hypothesis prospectively. The proposed susceptibility mechanisms include an immune-mediated reaction tied to the HLA-B*35:01 allele van Breemen 2025. Genotyping a consecutive series of adjudicated cases against exposed controls would either produce the first predictive test in this space or retire the hypothesis. Neither has happened.

Garcinia Cambogia — its own safety story, not its category's

The risk that belongs to this product rather than to its category is hepatocellular liver injury, and the record is specific enough to print. A 2025 review searched multiple adverse-event databases and the peer-reviewed literature and identified more than 200 reported liver-injury events associated with Garcinia consumption. Thirty-four published case reports included one death and nine liver transplants; 17 carried CIOMS/RUCAM causality scores in the possible-to-highly-probable range, and in one case causality was confirmed by rechallenge. The pattern was elevated alanine and aspartate aminotransferase with a high ratio of alanine aminotransferase to alkaline phosphatase, which is the hepatocellular signature. This review is what prompted the United States Pharmacopeia to revise its Garcinia dietary-ingredient monographs to carry a cautionary statement about liver damage van Breemen 2025.

Now the denominator, because a case count without one is a scare rather than a risk. An analysis of national survey data estimated that 15.6 million US adults had consumed at least one botanical product with liver liability in the previous 30 days, a number the authors compared with the number taking non-steroidal anti-inflammatory drugs Likhitsup 2024. Against exposure on that scale, 34 published cases describes something rare and idiosyncratic. Rare and idiosyncratic is also how the drug-induced liver injury literature describes reactions nobody can predict in advance, which is why the monitoring above is a blood test rather than a symptom to watch for.

The category precedent is worth knowing and worth stating carefully. Muscletech Hydroxycut was recalled by its manufacturer in May 2009 after hepatotoxicity reports. The subsequent case series adjudicated by Drug-Induced Liver Injury Network methodology found 8 patients hospitalized, 3 of whom required liver transplantation, plus 9 further cases from the FDA MedWatch database including one fatal acute liver failure; causality was rated definite in 8, highly likely in 5, probable in 2 and possible in 2 Fong 2010. The careful part: that adjudication was of a MULTI-INGREDIENT PRODUCT. No single component was identified as the cause, and the paper's own conclusion generalizes to weight-loss supplements as a class rather than to any one plant. Anyone citing Hydroxycut as proof about garcinia specifically is going beyond what that series says.

One drug interaction has a mechanism proposed for it, and its evidence is in vitro. Prompted by 8 reports of hepatic adverse reactions, investigators tested Garcinia cambogia in combination with montelukast in cells and reported that the combination greatly reduced cell viability, raised intracellular reactive oxygen species and altered cytoplasmic Nrf2 expression Di Giacomo 2023. That is a hypothesis about an interaction, generated in culture, and it is reported here as one - not as a clinical finding.

The serotonergic interaction is the one most likely to be encountered and the least likely to be mentioned at the counter. Cases of serotonin toxicity and mania have been reported with these supplements Andueza 2021. Anyone taking a selective serotonin reuptake inhibitor, a serotonin-noradrenaline reuptake inhibitor, a triptan, tramadol, lithium or a monoamine oxidase inhibitor is in a different risk position from a healthy adult, and that is a prescriber's conversation rather than a shelf decision.

Two plain notes to finish. Gastrointestinal adverse events occurred about twice as often on hydroxycitric acid as on placebo in the pooled trials, which is the common and unremarkable side of this compound Onakpoya 2011. And nobody should take it with existing liver disease, in pregnancy, or alongside another product whose composition is not printed, because the injury described above is the kind that is only visible in a blood test until it is not. Nothing here is medical advice, and none of these statements has been evaluated by the Food and Drug Administration.

Sources read for this page

• Heymsfield SB. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA 1998;280(18):1596-1600 · PMID 9820262
• Onakpoya I. The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. J Obes 2011 · PMID 21197150
• Ismail A. Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase. Pathol Res Pract 2022 · PMID 36401980
• Batchuluun B. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov 2022 · PMID 35031766
• Donnelly KL. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005 · PMID 15864352
• Lawitz EJ. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. J Lipid Res 2022 · PMID 35835205
• Roumans KHM. Liver fat storage pathways: methodologies and dietary effects. Curr Opin Lipidol 2021 · PMID 33234776
• Tutunchi H. Effects of Hydroxycitric Acid Supplementation on Body Composition, Obesity Indices, Appetite, Leptin, and Adiponectin of Women with NAFLD on a Calorie-Restricted Diet. Int J Clin Pract 2023 · PMID 37476001
• H Baky M. Recent Advances in Garcinia cambogia Nutraceuticals in Relation to Its Hydroxy Citric Acid Level. A Comprehensive Review of Its Bioactive Production, Formulation, and Analysis with Future Perspectives. ACS Omega 2022 · PMID 35936438
• Mena-García A. Quality Evaluation of Dietary Supplements for Weight Loss Based on Garcinia cambogia. Nutrients 2022 · PMID 35893931
• van Breemen RB. Hepatotoxicity of dietary supplements containing Garcinia gummi-gutta (L.) N. Robson. Pharm Biol 2025 · PMID 41262061
• Andueza N. Risks Associated with the Use of Garcinia as a Nutritional Complement to Lose Weight. Nutrients 2021 · PMID 33572973
• Fong TL. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010 · PMID 20104221
• Di Giacomo S. Interaction of Garcinia cambogia (Gaertn.) Desr. and Drugs as a Possible Mechanism of Liver Injury: The Case of Montelukast. Antioxidants (Basel) 2023 · PMID 37760074
• Likhitsup A. Estimated Exposure to 6 Potentially Hepatotoxic Botanicals in US Adults. JAMA Netw Open 2024 · PMID 39102266

How you would know if it worked

Garcinia Cambogia — safety & side effects

Bloodwork to run alongside Garcinia Cambogia

Baseline first, then again at 8–12 weeks.

The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.

Check results you already have → · All 103 markers A–Z

Garcinia Cambogia — frequently asked questions

What Garcinia Cambogia is used for

Garcinia Cambogia appears under 1 goal in the goal router.

Related Metabolic & Weight supplements

← Browse the full Supplement Vault

↑ Back to on this page